Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of SD-101 cream in epidermolysis bullosa
2014-002288-14Phase 3Completed
- Sponsor
- Scioderm
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epidermolysis bullosa simplex (EBS), Recessive Dystrophic Epidermolysis Bullosa (RDEB) and epidermolysis bullosa (EB) comparing SD-101-6.0 cream with Placebo cream (SD-101-0.0) (2 arms). Primary endpoints: Co-primary efficacy endpoints and Safety endpoints. Started Jul 2014; status: completed.
02
Drugs
allantoin
03
Conditions
epidermolysis bullosa simplex (EBS)Recessive Dystrophic Epidermolysis Bullosa (RDEB)epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2014-002288-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002288-14.